Effect of AT1 receptor blockade on endothelial function in essential hypertension

被引:104
作者
Klingbeil, AU [1 ]
John, S [1 ]
Schneider, MP [1 ]
Jacobi, J [1 ]
Handrock, R [1 ]
Schmieder, RE [1 ]
机构
[1] Univ Erlangen Nurnberg, Med Klin 4, Dept Med 4, D-90471 Nurnberg, Germany
关键词
AT(1) receptor blocker; essential hypertension; endothelial function; nitric oxide availability;
D O I
10.1016/S0895-7061(02)03154-0
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: Angiotensin II adversely affects endothelial function and NO availability. We analyzed the effect of AT(1) receptor blockade on endothelium-dependent vasodilation and basal nitric oxide (NO) production and release in hypertensive patients. Methods and Results: Sixty patients (53 +/- 10 years) with essential hypertension were randomized to 6 weeks of double-blind therapy with either valsartan (80 mg), hydrochlorothiazide (HCTZ) (25 mg), or placebo once daily. Basal NO production and release was assessed by measuring forearm blood flow (FBF) in response to intra-arterial infusion of N-G-monomethyl-L-arginine (L-NMMA), and endothelium-dependent vasodilation by measuring FBF in response to intra-arterial administration of acetylcholine, respectively. Intra-arterial infusion of noradrenaline and sodium nitroprusside was used to assess endothelium-independent changes in FBF. Blood pressure (BP) similarly decreased with active treatments (P < .001). After valsartan treatment, the decrease of FBF in response to L-NMMA was augmented (4 mumol/min L-NMMA, -1.3 +/- 1.2 after v -0.5 +/- 1.1 mL/min/100 mL before therapy, P < .02; 8 mumol/min L-NMMA: -1.7 +/- 1.3 after v -1.1 +/- 1.2 mL/min 100 mL before therapy, P < .05). No improvement was found after placebo or HCTZ treatment. Changes in L-NMMA-induced decrease of FBF with valsartan treatment were not related to BP changes. Neither drug substantially modified the response of FBF induced by intra-arterial infusion of acetylcholine, noradrenaline, and sodium nitroprusside. Conclusions: The AT(1) receptor blockade with valsartan improved basal NO production and release. The effect seems to be BP independent, as BP reduction with HCTZ failed to increase NO availability. (C) 2003 American Journal of Hypertension, Ltd.
引用
收藏
页码:123 / 128
页数:6
相关论文
共 37 条